Skip to main navigation
Contact Us
Join Us
LinkedIn
Our Company
About Us
Governance
Our Culture
Our Commitment
Diabetic Macular Edema ׀ OCS-01
Post-Ocular Surgery ׀ OCS-01
Dry Eye Disease ׀ OCS-02
Uveitis ׀ OCS-02
Acute Optic Neuritis ׀ OCS-05
Our Innovation
Pipeline
Clinical Trials
Science
Publications
Investors and Media
Column
Overview
Stock Information
News Releases
Events & Presentations
Column
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
Our Company
About Us
Governance
Our Culture
Our Commitment
Diabetic Macular Edema ׀ OCS-01
Diabetic Macular Edema
Post-Ocular Surgery ׀ OCS-01
Post-Ocular Surgery
Dry Eye Disease ׀ OCS-02
Dry Eye Disease
Uveitis ׀ OCS-02
Uveitis
Acute Optic Neuritis ׀ OCS-05
Acute Optic Neuritis
Our Innovation
Pipeline
Clinical Trials
Science
Publications
Investors and Media
Column
Overview
Stock Information
News Releases
Events & Presentations
Column
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources
Event Details
Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu
Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu
Q3 2024 Earnings
Nov 7, 2024
Rethinking Ophthalmology
News
Events
Pipeline
